Resumen de acción AUROPHARMA
Aurobindo Pharma Limited se dedica a la fabricación de formulaciones genéricas e ingredientes farmacéuticos activos en India, Estados Unidos, Europa y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Competidores de Aurobindo Pharma Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,103.40 |
| 52 Week High | ₹1,177.10 |
| 52 Week Low | ₹581.25 |
| Beta | 0.58 |
| 1 Month Change | 4.78% |
| 3 Month Change | -4.12% |
| 1 Year Change | 78.70% |
| 3 Year Change | 14.08% |
| 5 Year Change | 38.05% |
| Change since IPO | 1,548.22% |
Noticias y actualizaciones recientes
Recent updates
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50
Feb 11Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 08These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Nov 10Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet
Aug 19Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 15Rentabilidad de los accionistas
| AUROPHARMA | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | -1.0% | -0.1% | 1.8% |
| 1Y | 78.7% | 55.9% | 46.4% |
Volatilidad de los precios
| AUROPHARMA volatility | |
|---|---|
| AUROPHARMA Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1986 | 23,451 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited se dedica a la fabricación de formulaciones genéricas e ingredientes farmacéuticos activos en India, Estados Unidos, Europa y a escala internacional. Ofrece formulaciones en forma de medicamentos orales, inyectables y de venta libre; e ingredientes farmacéuticos activos (API) para biosimilares, dermatología, respiratorio, vacunas y péptidos, así como oncología, hormonas y productos estériles. La empresa también suministra medicamentos antirretrovirales para las personas y los niños que viven con el VIH; y AuroZymes, un producto biocatalizador para uso en las industrias farmacéutica y química.
Resumen de fundamentos de Aurobindo Pharma Limited
| Estadísticas fundamentales de AUROPHARMA | |
|---|---|
| Capitalización bursátil | ₹646.52b |
| Beneficios(TTM) | ₹27.70b |
| Ingresos (TTM) | ₹278.95b |
23.3x
Ratio precio-beneficio (PE)2.3x
Ratio precio-ventas (PS)¿Está AUROPHARMA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AUROPHARMA | |
|---|---|
| Ingresos | ₹278.95b |
| Coste de los ingresos | ₹130.37b |
| Beneficio bruto | ₹148.58b |
| Otros gastos | ₹120.87b |
| Beneficios | ₹27.70b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 30, 2024
| Beneficios por acción (BPA) | 47.28 |
| Margen bruto | 53.26% |
| Margen de beneficio neto | 9.93% |
| Ratio deuda/patrimonio | 23.6% |
¿Cómo se ha desempeñado AUROPHARMA a largo plazo?
Ver rendimiento histórico y comparativa